While the authors demonstrated that JNS-140 activated PP2A and reduced tumor growth with no signs of toxicity in vivo (Fig. 4C), they did not define whether increased B56γ-PP2A formation was responsible for the observed increase in PP2A activity or validate that JNS-140 treatment stabilized the formation of this holoenzyme. This evidence concerns the gene PTPA and neoplasm.